Pratz, K. W. Et Al. 2022. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia with Venetoclax and Azacitidine. Journal of Clinical Oncology , vol.40, no.8 , 855-865.

Pratz, K. W., Jonas, B. A., Pullarkat, V., Recher, C., Schuh, A. C., Thirman, M. J., ... Garcia, J. S.(2022). Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia with Venetoclax and Azacitidine. Journal of Clinical Oncology , vol.40, no.8, 855-865.

Pratz, Keith Et Al. "Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia with Venetoclax and Azacitidine," Journal of Clinical Oncology , vol.40, no.8, 855-865, 2022

Pratz, Keith W. Et Al. "Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia with Venetoclax and Azacitidine." Journal of Clinical Oncology , vol.40, no.8, pp.855-865, 2022

Pratz, K. W. Et Al. (2022) . "Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia with Venetoclax and Azacitidine." Journal of Clinical Oncology , vol.40, no.8, pp.855-865.

@article{article, author={Keith W. Pratz Et Al. }, title={Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia with Venetoclax and Azacitidine}, journal={Journal of Clinical Oncology}, year=2022, pages={855-865} }